Aims: To determine whether edaravone (MCI-186), a free radical scavenger, can reduce the macular edema and improve the visual acuity after arteriovenous sheathotomy in eyes with a branch retinal vein occlusion (BRVO).
Methods: Forty-seven eyes of 47 consecutive patients with a BRVO who were treated with arteriovenous sheathotomy were analyzed. The patients were assigned prospectively to either Group R who received 30 mg of edaravone (Radicut®) systemically during the vitrectomy, or Group N who did not receive any drugs. The postoperative visual acuity was measured before and 12 months after the operation.
Results: At 12 month postoperatively, the best-corrected visual acuity (BCVA) in logarithm of the minimum angle of resolution (logMAR) units improved significantly from 0.22 to 0.56 logMAR units in Group R and from 0.20 to 0.27 units in Group N (P = 0.016). Twenty-three of 27 cases (85%) in Group R and 4 of 15 cases (27%) in Group N showed an improvement in BCVA of >0.2 logMAR units (P = 0.0025).
Conclusion: The better visual acuity in patients given edaravone than those without endaravone during the arteriovenous sheathotomy suggests that edaravone improved the physiology of the retinal cells after the arteriovenous sheathotomy.
Statistics from Altmetric.com
This manuscript is Open Access.